Tag Archives: NASDAQ:AKBA

Akebia Therapeutics (AKBA) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $17. The company’s shares closed yesterday at $8.43. Yang said: “We expect Akebia to compete with two

RBC Capital Sticks to Their Hold Rating for Akebia Therapeutics (AKBA)

In a report released yesterday, Kennen MacKay from RBC Capital reiterated a Hold rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $13. The company’s shares closed yesterday at $8.22, close to its 52-week low of $7.77. According

Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA), Acceleron Pharma (NASDAQ: XLRN) and uniQure NV (NASDAQ: QURE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akebia Therapeutics (NASDAQ: AKBA), Acceleron Pharma (NASDAQ: XLRN) and uniQure NV (NASDAQ: QURE) with bullish sentiments. Akebia Therapeutics (AKBA) In a report

Mizuho Securities Thinks Akebia Therapeutics’ Stock is Going to Recover

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $9.51, close to its 52-week low of $8.93. According

Mizuho Securities Sticks to Its Buy Rating for Akebia Therapeutics

Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $24. The company’s shares closed yesterday at $13.52. According to TipRanks.com, Yang is a 5-star analyst with an average

Mizuho Securities Releases a Buy Rating on Akebia Therapeutics

Mizuho Securities analyst Difei Yang assigned a Buy rating to Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $24. The company’s shares closed yesterday at $14.45. Yang noted: “We had a chance to catch up with CEO